FMBA of Russia (SPbSRIVS), is implementing the first project for the Russian Federation to transfer technologies for the production of immunobiological medicines, in particular vaccines for the prevention of influenza, abroad.
As part of this work, the construction of the Latin American Biotechnology Institute MECHNIKOV in the Republic of Nicaragua has been completed and the technology transfer phase has begun.
The project of FMBA of Russia in Latin America is implemented within the framework of the work of the Russia-Nicaragua intergovernmental commission. October 22th 2016 an official event took place, timed to the completion of the construction of the enterprise and the beginning of validation and certification work of the production factory.
The market of pharmaceutical and immunobiological medicines in Latin America and the Caribbean Basin (LACB) in 2015 exceeded $96 billion.
In total, the aggregate market of these countries, with a population exceeding 600 million people, is about 8% of the world market, with a growth rate of 12% annually, and in the part of immunobiological medicines, especially bio-like, as high as 38%.
According to SPbSRIVS experts, in the future the dynamics of the market growth will be strengthened due to the demographic effect of population aging. In most countries of the region, by 2040 the share of the population over 50 will double, which certainly will cause a surge in the consumption of medical services and medicines.
Given the high share of social support in the countries of the Latin American region and the forced import policy with regard to the acquisition of immunobiological medicines and vaccines, the public procurement sector for medicines has been chosen as the priority for establishing a presence in the region. The Ministry of Health and Social Welfare in most countries of the region are interested in long-term cooperation related to the provision of sufficient quantities of vaccines at fixed prices.
As a result of the project, MECHNIKOV succeeded in creating a favorable environment for the formation of a basis for the transfer of technology for the production of a preventive influenza vaccine. Transfer of technology is a painstaking work divided into appropriate stages, work that has a clear sequence of actions, as well as standards developed by WHO and its compliance is an obligatory procedure.
Stages of transfer